<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060567</url>
  </required_header>
  <id_info>
    <org_study_id>E7070-A001-106</org_study_id>
    <nct_id>NCT00060567</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study of E7070 in Combination With Irinotecan</brief_title>
  <official_title>Phase I Dose-Finding Study of E7070 in Combination With Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung&#xD;
      tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one&#xD;
      of two E7070 dose escalation schemes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.</measure>
    <time_frame>1st arm: D1, D8, Q3WK; 2nd arm: D1, D8, Q3WK; 3rd arm: D1, D15, Q4WK</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, E7070 activity and Pharmacokinetics</measure>
    <time_frame>1st arm: D1, D8, Q3WK; 2nd arm: D1, D8, Q3WK; 3rd arm: D1, D15, Q4WK</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active combination of E7070 and irinotecan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active combination of E7070 and irinotecan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active combination of E7070 and irinotecan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7070 + irinotecan combination</intervention_name>
    <description>Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan + E7070 combination</intervention_name>
    <description>Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan + E7070 combination</intervention_name>
    <description>Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a histologically or cytologically confirmed refractory small cell&#xD;
             lung carcinoma or relapsed pancreatic cancer.&#xD;
&#xD;
          2. Patients should not have received more than two previous regimens of chemotherapy&#xD;
             (prior epidermal growth factor directed therapy antiangiogenic therapy, or&#xD;
             capecitabine do not constitute a previous regimen),&#xD;
&#xD;
          3. Patients must be aged greater than or equal to 18 years,&#xD;
&#xD;
          4. Patients must be ambulatory and have a Karnofsky performance status greater than or&#xD;
             equal to 70%,&#xD;
&#xD;
          5. Patients must have a life expectancy of greater than or equal to 3 months,&#xD;
&#xD;
          6. Patients must meet the following screening hematologic values:&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 10g /dL&#xD;
&#xD;
               -  Absolute Neutrophil Count greater than or equal to 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets greater than or equal to 100 x 109/L,&#xD;
&#xD;
          7. Patients must meet the following screening values for liver function:&#xD;
&#xD;
               -  Serum bilirubin less than or equal to 1.5 x upper limits of normal (ULN)&#xD;
&#xD;
               -  ALAT and ASAT less than or equal to 2.5 x ULN (unless related to liver&#xD;
                  metastases, in which case less than or equal to 5 x ULN),&#xD;
&#xD;
          8. Patients must have serum creatinine less than or equal to 1.5 x ULN,&#xD;
&#xD;
          9. Patients must be willing and able to comply with the study protocol for the duration&#xD;
             of the study, and&#xD;
&#xD;
         10. Patients must give written informed consent prior to any study-specific screening&#xD;
             procedures with the understanding that the patient may withdraw consent at any time&#xD;
             without prejudice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received chemotherapy or radiation therapy (except palliative) or&#xD;
             who have had major surgery within four weeks of treatment start,&#xD;
&#xD;
          2. Patients who have received chemotherapy without recovering from chemotherapy related&#xD;
             toxicity (defined as grade 1 or less) at study entry,&#xD;
&#xD;
          3. Patients who have received palliative radiation therapy without recovering from&#xD;
             radiation associated toxicity at study entry,&#xD;
&#xD;
          4. Patients with a history of hypersensitivity to irinotecan,&#xD;
&#xD;
          5. Patients who experienced greater than or equal to Grade 3 toxicity during previous&#xD;
             therapy with irinotecan,&#xD;
&#xD;
          6. Women who are pregnant or breastfeeding. Women of childbearing potential with either a&#xD;
             positive pregnancy test at screening or no pregnancy test. Women of childbearing&#xD;
             potential unless (1) surgically sterile or (2) using adequate measures of&#xD;
             contraception in the opinion of the Investigator (postmenopausal women must be&#xD;
             amenorrheic for at least 12 months to be considered of non-childbearing potential),&#xD;
&#xD;
          7. Fertile men who are not willing to use contraception or fertile men with a female&#xD;
             partner who is not willing to use contraception,&#xD;
&#xD;
          8. Any history of uncontrolled seizures; CNS disorders; or psychological, familial,&#xD;
             sociological or geographical conditions, judged by the Investigator to be clinically&#xD;
             significant, and/or potentially capable of precluding informed consent or adversely&#xD;
             affecting compliance with the study protocol and follow-up schedule,&#xD;
&#xD;
          9. Patients must not have untreated brain metastases (Patients who have been treated for&#xD;
             CNS metastases must be asymptomatic and radiologically stable for 4 weeks prior to&#xD;
             entry),&#xD;
&#xD;
         10. Patients with a history of conjugated hyperbilirubinemia,&#xD;
&#xD;
         11. Patients with clinically significant cardiac or cardiovascular impairment,&#xD;
&#xD;
         12. Patients with severe uncontrolled intercurrent infections,&#xD;
&#xD;
         13. Patients with organ allografts,&#xD;
&#xD;
         14. Patients who are receiving investigational drug treatment, immunotherapy, or biologic&#xD;
             therapy. Treatment must have been completed four weeks prior to entry into the study&#xD;
             and patients must have recovered from any associated toxicity.&#xD;
&#xD;
         15. Patients with a history of hypersensitivity to sulfonamides,&#xD;
&#xD;
         16. Patients with surgically resectable metastatic disease,&#xD;
&#xD;
         17. Patients who are known to be positive for hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis B core antibody (HBcAb), Hepatitis C antibody, or human immunodeficiency&#xD;
             virus,&#xD;
&#xD;
         18. Patients with significant disease, in the Investigator's opinion, that would exclude&#xD;
             the patient from the study,&#xD;
&#xD;
         19. Patients who are legally incapacitated,&#xD;
&#xD;
         20. Patients who have a repeated demonstration of QTc greater than 470 ms (Bazett's&#xD;
             correction),&#xD;
&#xD;
         21. Patients with tumor, including metastasis, that is surgically resectable,&#xD;
&#xD;
         22. Patients with clinical symptoms from brain metastasis,&#xD;
&#xD;
         23. Patients taking steroids for the treatment of brain metastases, or&#xD;
&#xD;
         24. Patients with leptomeningeal metastasis,&#xD;
&#xD;
         25. Patients who have a history of additional risk factors for torsades de pointes (e.g.,&#xD;
             heart failure) or family history of Long QT Syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eisai Medical Services</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 7, 2003</study_first_submitted>
  <study_first_submitted_qc>May 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2003</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E7070</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>hydrochloride</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

